Investigational monoclonal antibody to treat Ebola is safe in adults, trial indicates
from NIH via Infection Control Today
The investigational Ebola treatment mAb114 is safe, well-tolerated and easy to administer, according to findings from an early stage clinical trial published in The Lancet. Eighteen healthy adults received the monoclonal antibody as part of a phase 1 clinical trial that began in May 2018 at the National Institutes of Health Clinical Center in Bethesda, Maryland.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063